Table 1 Baseline characteristics for 623 central Australian cohort participants stratified by baseline ACR level
From: Clinical outcomes associated with albuminuria in central Australia: a cohort study
All participants | ACR <3.5 mg/mmol | ACR ≥3.5 mg/mmol | |
|---|---|---|---|
(n = 623) | (n = 413) a | (n = 180) a | |
Age at recruitment | 30 (15–85) | 28 (15–79) | 35 (16–85) |
Age at end of follow-up | 40 (19–90) | 38 (19–89) | 45 (27–90) |
Years of follow-up | 9.8 (0.5-10.8) | 9.8 (0.9-10.8) | 9.8 (0.5-10.8) |
Person-years of follow up | 6009 | 4001 | 1734 |
Male gender | 267 (42.9) | 189 (45.8) | 67 (37.2) |
Diabetes at baseline | 79 (12.7) | 28 (6.8) | 47 (26.1) |
Fasting glucose, mmol/L | 4.4 (2.7-19.8) | 4.3 (2.7-17.2) | 4.7 (3.2-19.8) |
BMI, kg/mb | 25.2 (13.4-51.1) | 24.4 (13.4-48.4) | 26.6 (15.5-51.1) |
WHR | 0.87 (0.70-1.33) | 0.86 (0.70-1.33) | 0.89 (0.73-1.20) |
Alcohol abstinence | 395 (62.3) | 244 (40.26) | 132 (66.3) |
Current smoker | 177 (29.2) | 131 (32.3) | 42 (24.1) |
Hypertension | 127 (20.4) | 57 (13.8) | 64 (35.6) |
Systolic BP, mmHg | 125 (93–198) | 124 (95–174) | 130 (93–198) |
Diastolic BP, mmHg | 72 (44–119) | 70 (44–105) | 75 (51–117) |
ACEi use | 1 (0.2) | 1 (0.2) | 0 |
Other BP medication use | 13 (2.1) | 6 (1.5) | 6 (3.3) |
Homocysteine, μmol/L | 13.5 (4.0-46.1) | 13.2 (4.0-46.1) | 14.1 (5.9-41.2) |
Prevalent UTI | 42 (6.7) | 26 (6.3) | 15 (8.3) |
Prevalent haematuria | |||
Nil | 442 (70.9) | 303 (73.4) | 111 (61.7) |
Trace | 70 (11.2) | 48 (11.6) | 22 (12.2) |
Small | 42 (6.7) | 25 (6.1) | 17 (9.4) |
Moderate | 30 (4.8) | 21 (5.1) | 8 (4.4) |
Large | 39 (6.3) | 16 (3.9) | 22 (12.2) |
KHA Matrix Green Zoneb | 201 (64.4) | 201 (100.0) | 0 |
KHA Matrix Yellow Zoneb | 82 (26.3) | 0 | 82 (73.9) |
KHA Matrix Red Zoneb | 29 (9.3) | 0 | 29 (26.1) |